Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dialysis-Dependent Chronic Kidney Disease Clear all
Withdrawn Phase 3 Interventional

Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

NCT03242967
View directory record Official record
Conditions
Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Northridge, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2018 · Synced Jul 22, 2026, 12:51 AM EDT
Completed Phase 4 Interventional Results available

KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial)

NCT03236246
View directory record Official record
Conditions
Chronic Kidney Diseases, Iron Deficiency Anemia
Interventions
KRX-0502
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
28
States / cities
Phoenix, Arizona • Chula Vista, California • El Centro, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Jul 22, 2026, 12:51 AM EDT
Terminated Phase 3 Interventional Results available

A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease

NCT01155375
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferumoxytol, Oral Iron
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
6 Months to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Jul 22, 2026, 12:51 AM EDT
Terminated Phase 3 Interventional Results available

A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease

NCT01264679
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferumoxytol
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
6 Months to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Jul 22, 2026, 12:51 AM EDT
Completed Phase 3 Interventional Results available

KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD

NCT02268994
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
ferric citrate, Placebo
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
36
States / cities
Phoenix, Arizona • Tempe, Arizona • Glendale, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Jul 22, 2026, 12:51 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

NCT02892149
View directory record Official record
Conditions
Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
3,554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
127
States / cities
Huntsville, Alabama • Mesa, Arizona • Pine Bluff, Arkansas + 95 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Jul 22, 2026, 12:51 AM EDT
Completed Phase 2 Interventional Results available

Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa

NCT03799627
View directory record Official record
Conditions
Anemia, Dialysis-dependent Chronic Kidney Disease
Interventions
Vadadustat, Epoetin Alfa, Vadadustat TIW
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 99 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
41
States / cities
Fresno, California • Granada Hills, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Jul 22, 2026, 12:51 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)

NCT01977573
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863, rhEPO
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
25
States / cities
Peoria, Arizona • Azusa, California • La Mesa, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Jul 22, 2026, 12:51 AM EDT
Withdrawn Phase 4 Interventional

L-Arginine and Spironolactone Trial in Dialysis-Dependent ESRD

NCT01855334
View directory record Official record
Conditions
End Stage Renal Disease, Hemodialysis
Interventions
Spironolactone, L-arginine, Placebo
Drug · Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Jul 22, 2026, 12:51 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

NCT02865850
View directory record Official record
Conditions
Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
54
States / cities
Huntsville, Alabama • Mesa, Arizona • Anaheim, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2022 · Synced Jul 22, 2026, 12:51 AM EDT
Completed Phase 3 Interventional Results available

VIT45 Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

NCT00317239
View directory record Official record
Conditions
Anemia
Interventions
Ferrous Sulfate tablets, Ferric Carboxymaltose (FCM)
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
12 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Norristown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Jul 22, 2026, 12:51 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

NCT03140722
View directory record Official record
Conditions
Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions
vadadustat, epoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
18
States / cities
Bakersfield, California • Elk Grove, California • Encino, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Jul 22, 2026, 12:51 AM EDT
Withdrawn Phase 2 Interventional

Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia

NCT00609544
View directory record Official record
Conditions
Chronic Kidney Disease, Anemia
Interventions
Rilonacept
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
27
States / cities
Alexander City, Alabama • Muscle Shoals, Alabama • Cerritos, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Jul 22, 2026, 12:51 AM EDT
Completed Phase 3 Interventional

Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients

NCT00255437
View directory record Official record
Conditions
Anemia
Interventions
ferumoxytol or oral iron
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
13
States / cities
Phoenix, Arizona • Tempe, Arizona • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Jul 22, 2026, 12:51 AM EDT
Completed Phase 3 Interventional Results available

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease

NCT02940860
View directory record Official record
Conditions
Iron Deficiency Anaemia, Iron Deficiency Anemia, Chronic Kidney Disease
Interventions
Iron isomaltoside/ferric derisomaltose, Iron sucrose
Drug
Lead sponsor
Pharmacosmos A/S
Industry
Eligibility
18 Years and older
Enrollment
1,538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
141
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Chula Vista, California + 96 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Jul 22, 2026, 12:51 AM EDT
Completed Phase 3 Interventional

Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients

NCT00255424
View directory record Official record
Conditions
Anemia
Interventions
ferumoxytol or oral iron
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
19
States / cities
Encino, California • Riverside, California • Tarzana, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Jul 22, 2026, 12:51 AM EDT
Terminated Phase 3 Interventional Results available

Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy

NCT04741074
View directory record Official record
Conditions
CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese, Obesity, Severe Obesity
Interventions
Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution, Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution
Drug
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Danville, Pennsylvania • Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Jul 22, 2026, 12:51 AM EDT
Completed Phase 3 Interventional Results available

Long Term Safety Study of (VIT45) Extension Study: Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

NCT00317226
View directory record Official record
Conditions
Anemia
Interventions
Ferric Carboxymaltose (FCM)
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
12 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Norristown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Jul 22, 2026, 12:51 AM EDT
Completed Phase 2 Interventional Results available

4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease

NCT01587924
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863, rhEPO
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
42
States / cities
Paragould, Arizona • Tempe, Arizona • Pine Bluff, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Jul 22, 2026, 12:51 AM EDT
Completed Phase 3 Interventional Results available

Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

NCT00994318
View directory record Official record
Conditions
Iron Deficiency Anaemia, Chronic Kidney Disease
Interventions
FCM (Ferric carboxymaltose) high ferritin target, FCM (Ferric carboxymaltose) low ferritin target, Oral Iron (Ferrous sulphate)
Drug
Lead sponsor
Vifor Pharma
Industry
Eligibility
18 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Jul 22, 2026, 12:51 AM EDT
Completed Phase 3 Interventional Results available

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)

NCT03400033
View directory record Official record
Conditions
Anaemia
Interventions
Daprodustat tablets, Matching placebo tablets, Epoetin alfa vials, Saline vials or bags
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
23
States / cities
Mesa, Arizona • Fresno, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2021 · Synced Jul 22, 2026, 12:51 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

NCT02680574
View directory record Official record
Conditions
Anemia, Non-Dialysis-Dependent Chronic Kidney Disease
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
219
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscumbia, Alabama + 158 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2022 · Synced Jul 22, 2026, 12:51 AM EDT
Completed Phase 2 Interventional Results available

Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial

NCT02285920
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Spironolactone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 85 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Jul 22, 2026, 12:51 AM EDT
Completed Phase 4 Interventional Results available

Safety and Cardiovascular Efficacy of Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD

NCT02228408
View directory record Official record
Conditions
Chronic Hemodialysis (ESRD)
Interventions
Hydralazine/Isorsorbide Dinitrate, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Jul 22, 2026, 12:51 AM EDT